On April 12, 2018 Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported it will be presenting preclinical data from its SIRPaFc immune checkpoint inhibitor programs, TTI-621 and TTI-622, at the 109th Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (Press release, Trillium Therapeutics, APR 12, 2018, View Source [SID1234525284]). The meeting will be held April 14-18 in Chicago, IL. Details of the poster presentations are listed below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: "The CD47-blocking innate immune checkpoint inhibitor, TTI-621, triggers CD47-mediated tumor cell apoptosis"
Presenter: Julia Bershadsky Izrailit, Ph.D., Trillium Therapeutics Inc.
Date and Time: Apr 16, 2018 from 1:00 p.m. – 5:00 p.m.
CT Location: McCormick Place South, Exhibit Hall A, Poster Section 32
Abstract Number: 2720

Title: "TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with anti-tumor antibodies in both hematological and solid tumor models"
Presenter: Gloria Lin, Ph.D., Trillium Therapeutics Inc.
Date and Time: Apr. 16, 2018 from 1:00 p.m. – 5:00 p.m. CT
Location: McCormick Place South, Exhibit Hall A, Poster Section 32
Abstract Number: 2709